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Sarcopenic obesity and myosteatosis are associated
with higher mortality in patients with cirrhosis
Aldo J. Montano-Loza1*, Paul Angulo2, Judith Meza-Junco3, Carla M. M. Prado4, Michael B. Sawyer3, Crystal Beaumont3,
Nina Esfandiari3, Mang Ma1 & Vickie E. Baracos3
1
Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Edmonton, Alberta, Canada; 2Division of Digestive Diseases & Nutrition, University of Kentucky
Medical Center, Lexington, KY, USA; 3Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada; 4Department of Agricultural, Food and Nutritional
Sciences, Edmonton, Alberta, Canada

Abstract
Background and aims Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss
of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion
is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this
study, we aimed to establish the frequency and clinical signiﬁcance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients.
Methods We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT
scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body
mass index-speciﬁc cutoffs.
Results Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%),
alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B
virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353
had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months, P < 0.001), sarcopenic obesity (22 ± 3 vs. 95
± 22 months, P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months, P < 0.001) had worse median survival than patients without muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% conﬁdence
interval (CI) 1.44–2.77, P < 0.001], and myosteatosis (HR 1.42, 95% CI 1.02–1.07, P = 0.04) were associated with mortality.
Conclusions Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia
and myosteatosis are independently associated with a higher long-term mortality in cirrhosis.
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Introduction
Overweight and obesity are endemic in Western countries
comprising up to 35% of the total population.1,2 Overweight and obesity have been associated with development
of chronic liver disease, worsening of liver ﬁbrosis and progression to cirrhosis,3,4 and the body mass index (BMI) has
been considered an independent risk factor for the development of decompensation among cirrhotic patients of all
causes.5

Severe muscle depletion or sarcopenia is one of the most
common complications in cirrhosis,6–10 and despite its important role in the prognosis of cirrhosis, it is frequently
overlooked as body composition assessments can be challenging in cirrhotic patients with ﬂuid retention or who are
overweight or frankly obese.11,12
Muscularity assessment with cross-sectional imaging
studies has become an attractive index of nutritional status
evaluation in cirrhosis,13,14 and different methods have been
used for the estimation of the muscle mass from axial CT
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scans, such as the psoas muscle area, or the thickness of the
psoas muscle at different levels of lumbar spine (L3, L4) or at
the level of umbilicus,15–17 and the cross-sectional area of
muscle normalized for stature referred to as the L3 skeletal
muscle index (L3 SMI).18
The CT analysis is not biased by the ﬂuid overload that
frequently presents in decompensated cirrhosis, and
sarcopenia reﬂects a chronic detriment in general physical
condition, rather than acute severity of the liver disease.19
Sarcopenia in cirrhosis is part of the frailty complex present
in these patients, characterized by a decreased reserve and
resistance to stressors and predisposition to poor outcomes.20–23
Patients with cirrhosis may develop simultaneous loss of
skeletal muscle and gain of adipose tissue, culminating
in the condition of ‘sarcopenic obesity’.24,25 In addition,
muscle depletion is characterized by both a reduction in
muscle size and increased proportion of intermuscular and
intramuscular fat denominated ‘myosteatosis’. Myosteatosis
increases with age and adiposity26 and is associated
with metabolic abnormalities,27 decreased strength and
mobility.28
In this study, our goals were to establish the frequency and
factors associated with sarcopenia, sarcopenic obesity and
myosteatosis in a cohort of cirrhotic patients evaluated for
liver transplantation. In this fashion, we aimed to establish
the impact of these muscular abnormalities on the prognosis
of cirrhotic patients.

Sarcopenia, sarcopenic obesity and myosteatosis
evaluation

Six hundred and seventy-eight adult patients with cirrhosis
who were evaluated for liver transplantation between
January 2000 and May 2013 at the University of Alberta
Hospital (Edmonton, AB, Canada) and had an abdominal CT
scan including the third lumbar (L3) vertebrae as part of their
pre-transplant evaluation were evaluated.

The CT scans used for analysis were carried out as part of
the liver transplant assessment. A transverse CT image from
L3 was assessed from each scan. Images were analysed
with SliceOmatic V4.3 software (Tomovision, Montreal, QB,
Canada), which enables speciﬁc tissue demarcation using previously reported Hounsﬁeld unit (HU) thresholds.29 Skeletal
muscle is identiﬁed and quantiﬁed by HU thresholds of 29
to +150. Muscles in the L3 region encompass psoas, erector
spinae, quadratus lumborum, transversus abdominus, external and internal obliques, and rectus abdominus. The following HU thresholds were used for adipose tissues: 190 to
30 for subcutaneous and intermuscular adipose tissues30
and 150 to 50 for visceral adipose tissues.31 Using these
speciﬁc HU thresholds, measurements of the skeletal muscle
index are not inﬂuenced by the presence of ascites in patients
with cirrhosis. Cross-sectional areas (cm2) were automatically
computed by summing tissue pixels and multiplying by pixel
surface area. All CT images were analysed by two trained observers (C. B., and N. E.) who demonstrated an intra-observer
coefﬁcient variation of 1.3%. Cross-sectional area of muscle
and adipose tissue was normalized for stature (cm2/m2) as
reported elsewhere,18 and this value is referred to as the
L3 SMI. Cutoffs for sarcopenia were based on a CT-based
study in patients with solid tumours using optimal stratiﬁcation, a statistical method similar to receiver operator curve
analysis, to solve speciﬁc threshold values for L3 SMI in
relation to an outcome (death) (L3 SMI: ≤41 cm2/m2 for
women and ≤53 cm2/m2 for men with BMI ≥25 and
≤43 cm2/m2 in patients with BMI <25).32 Muscle attenuation indirectly measures fat inﬁltration in muscles. Mean
muscle attenuation in HU was reported for the entire muscle area at the third lumbar vertebra. We also, used
previous cutoff values for muscle attenuation previously associated with mortality, speciﬁcally <41 HU in patients with
a BMI up to 24.9, and <33 in those with a BMI ≥25.32
Finally, sarcopenic obesity was deﬁned as those patients
with concurrent sarcopenia and overweight or obesity
(BMI > 25 kg/m2).

Clinical and laboratory assessments

Statistical analyses

Data recovered from medical charts included gender, age,
weight, height, cirrhosis aetiology and liver biochemistries,
serum albumin, serum creatinine, international normalized
ratio (INR), Child–Pugh and model for end stage liver disease
(MELD) scores. Clinical, laboratory and radiological data used
for the analysis, and to calculate MELD and Child–Pugh scores
were obtained within 1 week from the CT used to quantify
muscle indices (time zero).

The Fisher’s exact probability was used to compare categorical variables, and the unpaired t-test was used to compare
differences in means of continuous variables. Survival was
calculated using Kaplan–Meier method, and they were compared using the Log Rank (Mantel–Cox) test. Patients were
followed from the date of the CT performed for muscle indices (time zero), until the date of death, liver transplantation
or last visit. As malignancy is strongly associated with muscle
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abnormalities,33 a survival sub-analysis excluding patients
with hepatocellular carcinoma (HCC) was performed.
Prognostic factors for mortality were analysed by Cox regression univariate and multivariate analyses. Biochemical
parameters, such as serum bilirubin, creatinine, sodium and
albumin, were included in the regression analysis as dimensional variables, whereas clinical variables, such as sarcopenia
and myosteatosis, were entered as categorical variables
(present or absent). Data are presented as the mean ±
standard error of the mean in tables and text.

Results
Clinical and biochemical features of patients with
sarcopenia, sarcopenic obesity and myosteatosis
Four hundred and ﬁfty-seven patients were men (67%), and
cirrhosis aetiology was hepatitis C virus in 269 patients
(40%), alcohol in 153 (23%), non-alcoholic steatohepatitis
(NASH)/cryptogenic in 96 (14%), autoimmune liver disease
in 55 (8%), hepatitis B virus in 43 (6%) and others in 5 patients (1%), and 291 patients had concomitant HCC (43%).
Two hundred and ninety-two patients had sarcopenia
(43%), 135 patients had sarcopenic obesity (20%), 353 patients had myosteatosis (52%) and 176 patients had both,
sarcopenia and myosteatosis (26%). In Figure 1, we illustrate
the overlapping of sarcopenia, myosteatosis and obesity
using a Venn diagram. Figure 2(A and B) illustrates two cirrhotic patients with severe obesity (BMI >40 kg/m2). Abdominal CT images in horizontal plane are images taken at

Figure 1 Venn diagram illustrating the association between sarcopenia,
myosteatosis and obesity.

A. J. Montano-Loza et al.

third lumbar vertebra, and the red colour indicates skeletal
muscles. CT at the left [Figure 2(A)] is from a male patient
with sarcopenic obesity, with BMI of 47 kg/m2 and L3 SMI
51 cm2/m2, and the CT at the right [Figure 2(B)] is from a female patient without sarcopenia, with BMI 42 kg/m2 and L3
SMI 49 cm2/m2.
Figure 2(C and D) illustrates two cirrhotic patients with
similar BMI (28 kg/m2). The patient at the left [Figure 2(C)]
had myosteatosis with low mean muscle attenuation
(21 HU), whereas the patient at the right [Figure 2(D)] had
normal mean muscle attenuation (40 HU).
Patients with sarcopenia were more frequently men
(P = 0.003), and less frequently overweight–obese
(P < 0.001), had lower weight (P < 0.001), BMI (P < 0.001),
L3 SMI (P < 0.001), and muscle attenuation (P < 0.001), had
higher height (P < 0.001), levels of serum creatinine
(P = 0.001), INR (P = 0.006), MELD (P = 0.006) and Child–Pugh
scores (P < 0.001) compared with patients with no muscular
abnormalities (Table 1).
Patients with sarcopenic obesity were older (P = 0.02), and
more frequently men (P = 0.001), had higher weight
(P < 0.001), and height (P < 0.001), and lower L3 SMI
(P < 0.001), and muscle attenuation (P < 0.001), higher levels
of serum creatinine (P < 0.001), and bilirubin (P = 0.02), MELD
(P = 0.009) and Child–Pugh scores (P < 0.001) compared with
patients with no muscular abnormalities (Table 1).
Lastly, patients with myosteatosis were older (P = 0.02), had
lower weight (P = 0.02), and lower frequency of overweight–
obesity (P < 0.001), lower L3 SMI (P < 0.001), muscle attenuation (P < 0.001), and albumin (P = 0.03), and higher creatinine
(P = 0.001), INR (P < 0.001), and higher MELD (P = 0.001) and
Child–Pugh scores (P < 0.001) compared with patients with
no muscular abnormalities (Table 1). Otherwise, there were
no signiﬁcant differences in clinical and biochemical features
among patients with sarcopenia, sarcopenic obesity and
myosteatosis and patients without muscular abnormalities
as shown in Table 1.

Survival in patients with sarcopenia, sarcopenic
obesity and myosteatosis
During mean follow-up of 21 ± 1 months (range 1–164 months),
248 patients received a liver transplant (37%), 259 died (38%)
and 171 (25%) were alive.
Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months,
P < 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22 months,
P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months,
P < 0.001) had worse median survival than patients without
muscular abnormalities.
Six-month probability of survival was 72%, 69% and 76% in
patients with sarcopenia, sarcopenic obesity and myosteatosis,
respectively, compared with 91% in patients without muscular
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 126–135
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Figure 2 Computed tomography images used for the muscularity assessment of patients with cirrhosis. Comparison of two cirrhotic patients with se2
2
2
vere obesity. (A) Male patient at the left had sarcopenic obesity (BMI 47 kg/m , L3 SMI 51 cm /m ), whereas a female patient at the right (B) had no
2
2
2
sarcopenia (BMI 42 kg/m , L3 SMI 49 cm /m ). Computed tomography images used for the muscle attenuation assessment of patients with cirrhosis
2
and comparison of two cirrhotic patients with similar BMI (28 kg/m ). (C) Patient at the left had low mean muscle attenuation (21 HU), whereas the
patient at the right (D) had normal mean muscle attenuation (40 HU).

abnormalities. The 1-year probability of survival was 62%, 59%,
68% and 85% in the same groups, respectively (Figure 3).
Moreover, patients with either sarcopenia, sarcopenic obesity and/or myosteatosis had signiﬁcantly worse survival than
patients with none of these ﬁndings (29 ± 4 vs. 95
± 22 months, P < 0.001), and patients who had both,
sarcopenic obesity and myosteatosis had the worse median
survival (19 ± 4 vs. 95 ± 22 months, P < 0.001).
Finally, cirrhotic patients with sarcopenia without obesity had
worse median survival than non-sarcopenic patients (22 ± 4 vs.
95 ± 16 months, P < 0.001), and patients with myosteatosis without sarcopenia had worse median survival than patients without
myosteatosis (41 ± 13 vs. 95 ± 22 months, P = 0.03), whereas patients with overweight–obesity had similar survival than patients
with normal BMI (41 ± 14 vs. 38 ± 6 months, P = 0.8).

Sub-analysis in patients without hepatocellular
carcinoma
In the sub-analysis excluding the 291 patients with concomitant HCC (n = 387), patients with sarcopenia (21 ± 3 vs. 82
± 27 months, P < 0.001), sarcopenic obesity (21 ± 2 vs. 82
± 27 months, P < 0.001), and myosteatosis (28 ± 7 vs. 82

± 27 months, P = 0.02) had worse median survival than patients without muscular abnormalities.

Features associated with mortality
By Cox regression analysis, biochemical values, including
levels of INR (P < 0.001), albumin (P = 0.002), bilirubin
(P < 0.001), sodium (P = 0.01), the L3 SMI (P < 0.001), and
muscle attenuation (P < 0.001), presence of sarcopenia
(P < 0.001), sarcopenic obesity (P < 0.001), myosteatosis
(P = 0.003), and MELD (P < 0.001) and Child–Pugh score
(P < 0.001) were signiﬁcantly associated with mortality in patients with cirrhosis (Table 2).
In the multivariate Cox analysis including the presence of
age, sodium, sarcopenia, myosteatosis, MELD, Child–Pugh
and NASH cirrhosis (excluding INR, albumin and bilirubin
to avoid colinearity, as they are included in either Child–
Pugh or MELD scores. Also sarcopenic obesity was not included, as this is a subset of sarcopenia), only sarcopenia
[hazard ratio (HR) 2.00, P < 0.001], myosteatosis (HR 1.42,
P = 0.04), MELD (HR 1.04, P = 0.001) and NASH cirrhosis
(HR 0.60, P = 0.01) were independently associated with
mortality (Table 3).
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Table 1 Features associated with sarcopenia, sarcopenic obesity and myosteatosis in patients with cirrhosis
Features
Age (years)
Gender (male:female)
Weight (kg)
Height (cm)
2
BMI (kg/m )
Obesity–overweight
Diabetes
2
2
L3 SMI (cm /m )
Muscle attenuation (HU)
Sarcopenia
Myosteatosis
Sarcopenic Obesity
Creatinine (nl, 50–115 μmol/L)
INR (nl, 0.8–1.2)
Albumin (nl, 35–50 g/L)
Bilirubin (nl, <20 μmol/L)
Sodium (nl 133–146 μmol/L)
MELD
Child–Pugh (A/B/C)
Child–Pugh (points)
Aetiology of Cirrhosis
Alcohol
HCV
AILDa
HBV
NASH-Cryptogenic
Othersb
Concomitant HCC

No muscular abnormalities
(n = 209)
56 ± 1*****
142:68*,***
83 ± 1**,*****
169 ± 0.5**
29 ± 0.5**,*******
169 (81)**
27 (13)
57 ± 1**
42 ± 0.5**
—
—
—
79 ± 3***,**
1.3 ± 0.3****,*****,**
33 ± 1********
67 ± 11*****
136 ± 1
13 ± 1****,******
43/135/31**
8 ± 0.2**
38 (18)
93 (44.5)
15 (7)
18 (9)
44 (21)
1 (0.5)
97 (46)

Sarcopenia
(n = 292)

Sarcopenic obesity
(n = 135)

57 ± 1
232:59*
77 ± 1**
174 ± 0.5**
25 ± 0.5**
135 (46)**
43 (15)
43 ± 0.5**
33 ± 0.5**
—
176 (60)
135 (46)
105 ± 7***
1.5 ± 0.4****
33 ± 0.5
99 ± 13
135 ± 0.5
15 ± 1****
37/149/106**
9 ± 0.2**
85 (29)
106 (36.5)
23 (8)
18 (6)
59 (20)
1 (0.5)
115 (39)

58 ± 1*****
113:22***
90 ± 2**
175 ± 0.5**
30 ± 0.5
—
20 (15)
45 ± 1**
32 ± 1**
—
77 (57)
—
114 ± 11**
1.5 ± 0.2*****
32 ± 1
125 ± 19*****
135 ± 1
16 ± 1******
12/64/59**
10 ± 0.2**
41 (30)
51 (38)
8 (6)
8 (6)
26 (19)
1 (1)
57 (42)

Myosteatosis
(n = 353)
58 ± 1*****
218:135
79 ± 1*****
170 ± 0.5
27 ± 0.5*******
192 (54)**
55 (16)
48 ± 1**
29 ± 0.5**
176 (50)
—
77 (22)
99 ± 5***
1.5 ± 0.3**
32 ± 1********
92 ± 9
135 ± 1
15 ± 1***
43/180/130**
10 ± 0.2**
86 (24)
131 (37)
30 (9)
14 (4)
88 (25)
4 (1)
145 (41)

AILD, autoimmune liver disease; BMI, body mass index; L3 SMI, lumbar third skeletal muscle index; CI, conﬁdence interval; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HU, Hounsﬁeld units; INR, international normalized ratio; MELD, model for
end stage liver disease; NASH, non-alcoholic steatohepatitis; nl, normal.
a
Include autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
b
Include alpha-1-antitrypsin deﬁciency, hemochromatosis and Wilson disease.
Numbers in parentheses are percentages.
Signiﬁcantly different from each other at the level of *P = 0.003; **P < 0.001; ***P = 0.001; ****P = 0.006; *****P = 0.02; ******P =
0.009; *******P = 0.002; ********P = 0.03.

Causes of death in patients with sarcopenia,
sarcopenic obesity and myosteatosis
Of the 259 patients who died, 54 patients (21%) died from liver
failure, 69 (27%) died from sepsis, 43 (17%) died from HCC progression, 18 (7%) died from hepatorenal syndrome, 9 patients
(3%) died from variceal bleeding and 66 patients (25%) died
from other reasons (cardiac arrest, cerebrovascular events,
trauma, extrahepatic malignancies, unknown and others).
In the analysis of the 259 who died, the frequency of
sepsis-related death was signiﬁcantly higher in cirrhotic patients with sarcopenia [49 (36%) vs. 20 (16%), P < 0.001;
Figure 4(A)], myosteatosis [47 (32%) vs. 22 (19%), P = 0.02;
Figure 4(B)], and sarcopenic obesity [24 (36%) vs. 45 (23%),
P = 0.05; Figure 4(C)] than patients without muscular abnormalities. Finally, patients without myosteatosis had higher
frequency of liver failure-related death [31 (27%) vs. 23
(16%), P = 0.03; Figure 4(B)] than patients with myosteatosis.
Otherwise, there were no signiﬁcant differences in the frequency of death related to liver failure, HCC progression,
hepatorenal syndrome, variceal bleeding and other

aetiologies among patients with and without muscular abnormalities [Figure 4(A–C)].

Outcomes after liver transplantation in patients
with sarcopenia, sarcopenic obesity and
myosteatosis
Two-hundred and forty-eight patients had a liver transplant,
and of them 112 (45%) had sarcopenia, 42 (17%) had
sarcopenic obesity and 116 (47%) had myosteatosis. Median
survival after liver transplant was not different among
sarcopenic and non-sarcopenic patients (117 ± 17 vs. 146
± 19 months, P = 0.4), patients with and without sarcopenic
obesity (114 ± 8 vs. 132 ± 112 months, P = 0.1), nor patients
with and without myosteatosis (117 ± 19 vs. 142 ± 17 months,
P = 0.1).
Sarcopenic patients had longer hospital stay (40 ± 4 vs. 25
± 3 days, P = 0.001) and intensive care unit stay after liver
transplantation (12 ± 2 vs. 6 ± 1 days, P = 0.005) than nonsarcopenic patients. Patients with myosteatosis had longer
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 126–135
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Figure 3 Kaplan–Meier curve indicating the survival of patients with sarcopenia (—), sarcopenic obesity (--), myosteatosis (--) and without muscular
abnormalities (—). The 6-month probability of survival was 72%, 69%, 76% and 91%, respectively (P < 0.001, log-rank test). The 1-year probability of
survival was 62%, 59%, 68%, and 85% in these same groups, respectively.

Table 2 Features associated with mortality by univariate Cox analysis in patients with cirrhosis
Features associated with mortality by univariate analysis
Age (years)
Gender (male:female)
Weight (kg)
2
BMI (kg/m )
Obesity-overweight
Diabetes
Creatinine (nl, 50–115 μmol/L)
INR (nl, 0.8–1.2)
Albumin (nl, 35–50 g/L)
Bilirubin (nl, <20 μmol/L)
Sodium (nl, 133–146 μmol/L)
2
2
L3 SMI (cm /m )
Men
Women
Muscle attenuation (HU)
Sarcopenia
Sarcopenic obesity
Myosteatosis
MELD Score
Child–Pugh (A/B/C)
Child–Pugh (points)
Alcohol cirrhosis
HCV cirrhosis
AILDa
HBV cirrhosis
NASH-cryptogenic cirrhosis
Concomitant HCC

Death (n = 259)

Alive (n = 419)

HR

95% CI

P-value

56 ± 1
172:87
80 ± 1
28 ± 1
165 (64)
20 (8)
96 ± 5
1.5 ± 0.4
32 ± 1
99 ± 12
135 ± 1
49 ± 1
52 ± 1

57 ± 1
285:134
79 ± 1
27 ± 1
254 (61)
59 (14)
91 ± 5
1.4 ± 0.2
33 ± 1
80 ± 9
136 ± 1
51 ± 1
54 ± 1

0.99
1.05
1.00
1.00
1.04
0.69
1.00
1.97
0.96
1.02
0.96
0.98
0.97

0.97–1.01
0.81–1.36
0.99–1.01
0.98–1.02
0.80–1.34
0.45–1.10
0.99–1.00
1.56–2.48
0.94–0.99
1.01–1.03
0.93–0.99
0.97–0.99
0.95–0.98

0.07
0.7
0.4
0.9
0.8
0.1
0.9
<0.001
0.002
<0.001
0.01
0.001
<0.001

52 ± 1

54 ± 1

0.98

0.96–1.01

0.3

34 ± 1
135 (52)
66 (26)
145 (56)
15 ± 1
27/161/71
9 ± 0.2
69 (27)
99 (38)
16 (6)
16 (6)
55 (21)
107 (41)

36 ± 1
157 (38)
69 (17)
208 (50)
14 ± 1
78/215/126
9 ± 0.2
84 (20)
169 (40)
39 (9)
27 (6)
98 (23)
184 (44)

0.96
1.98
1.72
1.45
1.05
1.43
1.07
1.15
1.16
0.74
1.17
0.72
0.89

0.95–0.98
1.55–2.53
1.30–2.28
1.13–1.85
1.03–1.07
1.17–1.74
1.01–1.14
0.87–1.52
0.91–1.50
0.44–1.22
0.71–1.94
0.53–0.97
0.69–1.15

<0.001
<0.001
<0.001
0.003
<0.001
<0.001
0.02
0.3
0.2
0.2
0.5
0.03
0.4

AILD, autoimmune liver disease; BMI, body mass index; CI, conﬁdence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; HR, hazard ratio; INR, international normalized ratio; MELD, model for end stage liver disease; NASH, non-alcoholic
steatohepatitis; nl, normal.
a
Include autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
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Table 3 Features associated with mortality by multivariate Cox analysis in patients with cirrhosis
Features associated with mortality by multivariate analysis

Death (n = 259)

Alive (n = 419)

HR

95% CI

P-value

56 ± 1
135 ± 1
135 (52)
145 (56)
15 ± 1
9 ± 0.2
55 (21)

57 ± 1
136 ± 1
157 (38)
208 (50)
14 ± 1
9 ± 0.2
98 (23)

0.99
0.97
2.00
1.42
1.04
0.92
0.60

0.97–1.02
0.93–1.01
1.44–2.77
1.02–1.99
1.02–1.07
0.85–1.01
0.40–0.89

0.8
0.1
<0.001
0.04
0.001
0.07
0.01

Age (years)
Sodium (nl, 133–146 μmol/L)
Sarcopenia
Myosteatosis
MELD score
Child–Pugh (points)
NASH-cryptogenic cirrhosis

CI, conﬁdence interval; HR, hazard ratio; MELD, model for end stage liver disease; NASH, non-alcoholic steatohepatitis; nl, normal.
Numbers in parentheses are percentages.
Variables included in the multivariate analysis were age, sodium, sarcopenia, myosteatosis, MELD, Child–Pugh, and NASH cirrhosis. INR,
bilirubin and albumin were not included to avoid colinearity, as they are included in either Child–Pugh or MELD scores. Also sarcopenic
obesity was not included, as this is a subset of sarcopenia.

intensive care unit stay (11 ± 2 vs. 6 ± 1 days, P = 0.02) than patients without myosteatosis, but no signiﬁcant differences in
hospital stay (36 ± 3 vs. 28 ± 3 days, P = 0.09), and patients with
sarcopenic obesity had no differences in hospital (35 ± 6 vs. 31
± 2 days, P = 0.6) and intensive care unit stay (8 ± 2 vs. 8
± 1 days, P = 0.9) than patients without sarcopenic obesity.
Finally, bacterial infections within the ﬁrst 90 days after
liver transplantation were more frequent for sarcopenic than
non-sarcopenic patients (26 vs. 15%, P = 0.04), but no signiﬁcant differences in bacterial infections were observed between patients with sarcopenic obesity (26 vs. 19%, P = 0.2)
and myosteatosis (20 vs. 20%, P = 0.6), compared with patients without these muscular abnormalities.

Discussion
Our study indicates that skeletal muscle abnormalities are
frequently present in patients with cirrhosis, with sarcopenia
being present in almost half of the patients; twenty percent
of them have sarcopenic obesity and fatty inﬁltration of skeletal muscle or myosteatosis being present in more than half
of cirrhotic patients.
Patients with cirrhosis and sarcopenia, sarcopenic obesity
and myosteatosis tend to be older, more frequently men
and have worse liver function assessed by MELD or Child–
Pugh scores compared with patients with no muscular abnormalities (Table 1).
Importantly, the presence of sarcopenia, sarcopenic obesity and myosteatosis were associated with worse survival
compared with cirrhotic patients with no muscular abnormalities. In fact, our study indicates that having sarcopenia and
myosteatosis increase the risk of mortality by 1.5- to twofold
compared with patients who do not have any of these muscular abnormalities.
The risk of mortality associated with the presence of muscular abnormalities (sarcopenia and myosteatosis) in cirrhotic
patients seems to be related to a higher frequency of sepsisrelated death (Figure 1). These ﬁndings are similar to a recent
study that found correlation between protein malnutrition

and sepsis in a cohort of hospitalized cirrhotic patients,34
and this might explain why conventional scores that reﬂect
mainly liver function, such as MELD and Child–Pugh, do not
detect mortality risks associated with skeletal muscle
abnormalities.10
Muscle wasting and fatty muscle inﬁltration in cirrhotic patients are part of the frailty complex present in these patients, characterized as decreased reserve and resistance to
stressors, resulting from cumulative declines across multiple
physiologic systems and predisposition to poor outcomes.20
Therefore, muscularity assessment including the L3 SMI and
muscle attenuation index are objective and reproducible,
and their assessment is not biased by overweight–obesity
and ﬂuid overload status that frequently is present in patients with decompensated cirrhosis. Moreover, skeletal muscle abnormalities in patients with cirrhosis seem to reﬂect a
chronic detriment in the general physical condition, rather
than acute severity of the liver disease.
The pathogenesis of sarcopenia and myosteatosis in cirrhotic patients is not completely elucidated, but it seems to
be the result of a complex interaction involving dysregulation
of fatty acid oxidation and ketogenesis, gluconeogenesis from
amino acids, glycogenolysis and selective utilization of aromatic amino acids in the liver and branched chain amino
acids in the skeletal muscle.35,36 Proinﬂammatory cytokines,
tumour necrosis factor-α, interleukin-6 and C-reactive protein
have been shown to mediate skeletal muscle catabolism,
leading to sarcopenia.37 Also, there is impairment of skeletal
muscle protein synthesis in portosystemic shunting because
of an increased expression of myostatin, a member of the
transforming growth factor beta superfamily,38,39 and autophagy in skeletal muscle mediated by hyperammonemia.40
One limitation of our study is that we used a deﬁnition
of sarcopenia based on cut-point values validated in a different population,32 as predeﬁned values for sarcopenia in
patients with cirrhosis have not been validated; however,
the values we used were derived from optimum stratiﬁcation of the L3 SMI, ﬁnding the most signiﬁcant P-values
to deﬁne gender-speciﬁc cut-points associated with mortality in patients with malignancy and obesity.32 We have
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Figure 4 Percentage of mortality related to liver failure, sepsis, hepatocellular carcinoma progression, variceal bleeding, hepatorenal syndrome
and others in cirrhotic patients with (A) sarcopenia, (B) myosteatosis and (C) sarcopenic obesity. GI, gastrointestinal; HCC, hepatocellular carcinoma;
HRS, hepatorenal syndrome.

already demonstrated that these values are useful to distinguish cirrhotic patients with sarcopenia and higher risk of
mortality,10 and cut-point values are very similar to a preliminary experience in patients with cirrhosis.41 Other potential limitation is that our cohort of cirrhotic patients
was mainly composed of either patients with advanced
liver disease or with HCC, so our results may not reﬂect
the broader population of cirrhosis. The prevalence of muscular abnormalities may be lower in a population-based cohort of cirrhotics.

In summary, despite the fact that skeletal muscle abnormalities, such as sarcopenia and myosteatosis, are not included in the conventional scores for prognosis in cirrhotic
patients, such as the MELD or Child–Pugh scores, its presence
should alert clinicians to the same extent as other complications do, such as ascites, hepatic encephalopathy or variceal
bleeding.14,13
As sarcopenia and myosteatosis are frequent complications in cirrhotic patients and are predictive of longer hospital
stays and a higher risk of perioperative bacterial infections
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after liver transplantation, but are not associated with increased post-liver transplant mortality,42 modiﬁcation of current allocation systems to include muscle abnormalities may
decrease mortality in patients with cirrhosis awaiting for liver
transplantation.
Cirrhotic patients are frequently overweight or obese, and
body composition assessments with CT images help to disclose otherwise occult sarcopenia and/or myosteatosis. Cirrhotic patients with sarcopenia and myosteatosis have a
worse prognosis compared with patients with no skeletal
muscular abnormalities, regardless of overall body weight
or BMI, mainly to higher risk of sepsis-related mortality.
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